Schizophrenia 15

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Schizophrenia 15

MalaCards integrated aliases for Schizophrenia 15:

Name: Schizophrenia 15 54 24 71 29 13 69
Sczd15 24 71
Schizophrenia Susceptibility Locus, Chromosome 22q13-Related 24
Schizophrenia Susceptibility Locus Chromosome 22q13-Related 71



schizophrenia 15:
Inheritance polygenic inheritance


External Ids:

OMIM 54 613950
MedGen 40 C3151380
MeSH 42 D012559
SNOMED-CT via HPO 65 191526005 58214004

Summaries for Schizophrenia 15

UniProtKB/Swiss-Prot : 71 Schizophrenia 15: A complex, multifactorial psychotic disorder or group of disorders characterized by disturbances in the form and content of thought (e.g. delusions, hallucinations), in mood (e.g. inappropriate affect), in sense of self and relationship to the external world (e.g. loss of ego boundaries, withdrawal), and in behavior (e.g bizarre or apparently purposeless behavior). Although it affects emotions, it is distinguished from mood disorders in which such disturbances are primary. Similarly, there may be mild impairment of cognitive function, and it is distinguished from the dementias in which disturbed cognitive function is considered primary. Some patients manifest schizophrenic as well as bipolar disorder symptoms and are often given the diagnosis of schizoaffective disorder.

MalaCards based summary : Schizophrenia 15, is also known as sczd15, and has symptoms including schizophrenia An important gene associated with Schizophrenia 15 is SHANK3 (SH3 And Multiple Ankyrin Repeat Domains 3). The drugs Dopamine and Haloperidol have been mentioned in the context of this disorder. Affiliated tissues include brain and testes.

Description from OMIM: 613950

Related Diseases for Schizophrenia 15

Symptoms & Phenotypes for Schizophrenia 15

Clinical features from OMIM:


Human phenotypes related to Schizophrenia 15:

id Description HPO Frequency HPO Source Accession
1 schizophrenia 32 HP:0100753

Drugs & Therapeutics for Schizophrenia 15

Drugs for Schizophrenia 15 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 240)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129722-12-9 60795
Chlorpromazine Approved, Vet_approved Phase 4 50-53-3 2726
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 132539-06-1 4585
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106266-06-2 5073
Ziprasidone Approved Phase 4 146939-27-7 60854
Perphenazine Approved Phase 4,Phase 2 58-39-9 4748
Clozapine Approved Phase 4 5786-21-0 2818
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
Nicotine Approved Phase 4,Phase 1 54-11-5 942 89594
Sulpiride Approved Phase 4 15676-16-1 5355
Metformin Approved Phase 4 657-24-9 14219 4091
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
17 tannic acid Approved, Nutraceutical Phase 4
18 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
19 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
22 decanoic acid Phase 4,Phase 3
23 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Haloperidol decanoate Phase 4,Phase 3
27 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
30 Quetiapine Fumarate Phase 4,Phase 3 111974-72-2
31 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
33 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 1
34 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Respiratory System Agents Phase 4,Phase 1,Phase 2
36 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Phase 1
37 Paliperidone Palmitate Phase 4,Phase 3,Phase 1
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
39 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Phase 1
40 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
42 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
43 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
44 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
45 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
46 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3
47 Antirheumatic Agents Phase 4,Phase 2,Phase 3
48 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 3
49 Salicylates Phase 4
50 Salicylsalicylic acid Phase 4

Interventional clinical trials:

(show top 50) (show all 230)

id Name Status NCT ID Phase Drugs
1 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
2 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
3 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
4 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated Completed NCT01157351 Phase 4 paliperidone;risperidone;haloperidole;perphenazine;aripiprazole;quetiapine;paliperidone palmitate;olanzapine
5 Salsalate as an Adjunctive Treatment for Patients With Schizophrenia Completed NCT01578486 Phase 4 salsalate
6 Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia Completed NCT00345033 Phase 4 Aripiprazole;Placebo
7 Smoking Relapse Prevention in Schizophrenia Completed NCT00320697 Phase 4 bupropion + nicotine patch + nicotine gum or lozenges;Placebo pill + placebo patch
8 A Placebo-Controlled, Cross-Over Trial of Aripiprazole Completed NCT00351936 Phase 4 Aripiprazole;placebo
9 Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment Completed NCT02676375 Phase 4 Combination Bupropion + NRTs;Monotherapy
10 Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder Completed NCT00216723 Phase 4 Aripiprazole
11 SOLIACS: Solian Solution in the Acute Setting Completed NCT00245674 Phase 4 amisulpride
12 Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents Completed NCT00545467 Phase 4 Aripiprazole
13 Trial of Nicotine Nasal Spray as an Aid for Smoking Cessation in Schizophrenia Completed NCT01010477 Phase 4 Nicotine Nasal Spray
14 A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients Completed NCT00634348 Phase 4 Aripiprazole;Ziprasidone
15 Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients Completed NCT01105481 Phase 4 Amisulpride add-on;Placebo add-on
16 Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder. Completed NCT00325689 Phase 4 Quetiapine or Risperidone + Aripiprazole;Quetiapine or Risperidone + placebo
17 A Switch Study of BMS-337039 in Schizophrenic Out-patients Completed NCT00232687 Phase 4 Aripiprazole;Aripiprazole
18 Effect on Cognitive Function of a Treatment With Aripiprazole Completed NCT00329810 Phase 4 Aripiprazole
19 A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients Completed NCT00300846 Phase 4 aripiprazole;Placebo
20 Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia Completed NCT01164059 Phase 4 Olanzapine;Flupentixol;Quetiapine;Aripiprazole;Haloperidol
21 Study in Adolescents With Schizophrenia or Bipolar Disorder Completed NCT00982020 Phase 4 Olanzapine
22 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up Completed NCT02534363 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
23 Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy Completed NCT00330863 Phase 4 Risperidone microspheres;Risperidone;Olanzapine;Quetiapine;Ziprasidone;Aripiprazole;Paliperidone
24 MEtformin and Lorcaserin for WeighT Loss in Schizophrenia Recruiting NCT02796144 Phase 4 Lorcaserin;Metformin;Placebo
25 Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism Recruiting NCT02237417 Phase 4 Standard of Care Oral antipsychotics;IM aripiprazole once monthly
26 A Pharmacokinetic Study of Paliperidone ER Recruiting NCT02433717 Phase 4 Paliperidone ER
27 European Long-acting Antipsychotics in Schizophrenia Trial Recruiting NCT02146547 Phase 4 Aripiprazole;Aripiprazole depot;Paliperidone;Paliperidone palmitate
28 Study of the Effect of Dosing on Clozapine Levels Active, not recruiting NCT02286206 Phase 4 Clozapine
29 The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia Active, not recruiting NCT01339858 Phase 4 N-Acetyl Cysteine
30 Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia Not yet recruiting NCT02736474 Phase 4 Naltrexone;Placebo Naltrexone;Bupropion;Placebo Bupropion
31 Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia Terminated NCT01576640 Phase 4 NRT;Bupropion SR 150mg bid
32 Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia Terminated NCT00712270 Phase 4 Aripiprazole;Risperidone
33 Safety and Tolerability of Varenicline in Schizophrenia (SATOVA) Withdrawn NCT00702793 Phase 4 Varenicline
34 Cardio Risk of Acute Schizophrenia Olanzapine Duke Withdrawn NCT00672464 Phase 4 Olanzapine;Metformin;Simvastatin
35 Bexarotene Treatment in Schizophrenia Unknown status NCT00141947 Phase 3 bexarotene (Targretin)
36 Treating Psychotic Symptoms of Young Individuals Presenting a First Episode of Schizophrenia: Comparison of Two State-of-the-Art Interventions Completed NCT00358709 Phase 3
37 New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia Completed NCT00161018 Phase 3 Quetiapine, Risperidone, Fluphenazine
38 Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689) Completed NCT01617200 Phase 3 Asenapine;Placebo Asenapine;Olanzapine;Placebo Olanzapine
39 A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia. Completed NCT00645307 Phase 3 Extended Release OROS® Paliperidone
40 A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688) Completed NCT01617187 Phase 3 Asenapine;Placebo Asenapine;Olanzapine;Placebo Olanzapine
41 A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305. Completed NCT00668837 Phase 3 Paliperidone
42 Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia Completed NCT01149655 Phase 3 Aripiprazole;Aripiprazole
43 Serotonin 1A Agonists and Cognition in Schizophrenia Completed NCT00178971 Phase 3 adjunctive treatment with buspirone;placebo
44 A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia Completed NCT00645099 Phase 3 olanzapine;paliperidone ER
45 An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia Completed NCT01009047 Phase 3 Paliperidone extended release (ER);Aripiprazole
46 A Comparison of the Pharmacokinetics and Safety of Long-acting Injectable Risperidone When Administered to Gluteal or Deltoid Intramuscular Injection Sites in Stable Schizophrenia Patients. Completed NCT00843687 Phase 3 Risperidone long-acting injectable
47 Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia Completed NCT00083668 Phase 3 Paliperidone ER
48 A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia Completed NCT01942161 Phase 2, Phase 3 Aripiprazole Low (2 mg/day);Aripiprazole Mid (6 - 12 mg/day);Aripiprazole High (24 - 30 mg/day)
49 Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia Completed NCT00615433 Phase 3 Lurasidone;Olanzapine;Placebo comparator;Lurasidone 40 mg tablets
50 Self-Management Therapy for Youth With Schizophrenia Completed NCT00000387 Phase 3

Search NIH Clinical Center for Schizophrenia 15

Genetic Tests for Schizophrenia 15

Genetic tests related to Schizophrenia 15:

id Genetic test Affiliating Genes
1 Schizophrenia 15 29 24 SHANK3

Anatomical Context for Schizophrenia 15

MalaCards organs/tissues related to Schizophrenia 15:

Brain, Testes

Publications for Schizophrenia 15

Variations for Schizophrenia 15

UniProtKB/Swiss-Prot genetic disease variations for Schizophrenia 15:

id Symbol AA change Variation ID SNP ID
1 SHANK3 p.Arg536Trp VAR_065800 rs387906933

ClinVar genetic disease variations for Schizophrenia 15:

id Gene Variation Type Significance SNP ID Assembly Location
1 SHANK3 NM_033517.1(SHANK3): c.3349C> T (p.Arg1117Ter) single nucleotide variant Pathogenic rs387906932 GRCh37 Chromosome 22, 51159610: 51159610
2 SHANK3 NM_033517.1(SHANK3): c.1606C> T (p.Arg536Trp) single nucleotide variant Pathogenic rs387906933 GRCh37 Chromosome 22, 51137225: 51137225

Expression for Schizophrenia 15

Search GEO for disease gene expression data for Schizophrenia 15.

Pathways for Schizophrenia 15

GO Terms for Schizophrenia 15

Sources for Schizophrenia 15

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....